The Path to Drawdown: Contraceptives
About 225 million women in lower-income countries lack the ability to choose whether and when to become pregnant. That leads to some 75 million unintended pregnancies each year. There's a similar deficiency in contraceptives in high-income countries, too. In the United States, for instance, nearly half of all pregnancies are unintended.
Securing the right to voluntary, high-quality family planning services and contraception around the world would have significant benefits on the health, welfare, and life expectancy of both women and their children.
Contraceptives, family planning and resources for women's health would also hugely benefit the environment. Every person in the world consumes resources and causes emissions throughout their life. If contraceptives are widely provided and women's health are secured, a more stable population size could help avoid up to 85.42 gigatons of greenhouse gases between 2020 and 2050.
Evofem Biosciences, Inc. (stock ticker: EVFM) is a biopharmaceutical company that offers a hormone-free contraceptive vaginal gel that is applied before sex. They are also working on a vaginal gel that reduces certain infections.
EVFM's Role in Drawdown
Evofem's flagship product, Phexxi, is an FDA-approved hormone-free prescription contraception that can be used only when women need it. It is a vaginal gel that's applied before sex and it acts as a contraceptive by keeping vaginal pH in the baseline range to make it difficult for semen to swim up the reproductive canal.
By providing women with more control over their sexual and reproductive health, Evofem contributes to the Drawdown solution of women's health.
EVFM: What We Like
We'll update this section once Evofem makes sustainability information available.